Literature DB >> 11942406

Telomere and telomerase in oncology.

Jiao Mu1, Li Xin Wei.   

Abstract

Shortening of the telomeric DNA at the chromosome ends is presumed to limit the lifespan of human cells and elicit a signal for the onset of cellular senescence. To continually proliferate across the senescent checkpoint, cells must restore and preserve telomere length. This can be achieved by telomerase, which has the reverse transcriptase activity. Telomerase activity is negative in human normal somatic cells but can be detected in most tumor cells. The enzyme is proposed to be an essential factor in cell immortalization and cancer progression. In this review we discuss the structure and function of telomere and telomerase and their roles in cell immortalization and oncogenesis. Simultaneously the experimental studies of telomerase assays for cancer detection and diagnosis are reviewed. Finally, we discuss the potential use of inhibitors of telomerase in anti-cancer therapy.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11942406     DOI: 10.1038/sj.cr.7290104

Source DB:  PubMed          Journal:  Cell Res        ISSN: 1001-0602            Impact factor:   25.617


  16 in total

1.  Relationship between microvessel density and telomerase activity in hepatocellular carcinoma.

Authors:  Yun-Feng Piao; Min He; Yang Shi; Tong-Yu Tang
Journal:  World J Gastroenterol       Date:  2004-07-15       Impact factor: 5.742

Review 2.  "Ins" and "Outs" of mesenchymal stem cell osteogenesis in regenerative medicine.

Authors:  Dean T Yamaguchi
Journal:  World J Stem Cells       Date:  2014-04-26       Impact factor: 5.326

3.  Dynamic alteration of telomerase expression and its diagnostic significance in liver or peripheral blood for hepatocellular carcinoma.

Authors:  Deng-Fu Yao; Wei Wu; Min Yao; Li-Wei Qiu; Xin-Hua Wu; Xiao-Qin Su; Li Zou; Deng-Bing Yao; Xian-Yong Meng
Journal:  World J Gastroenterol       Date:  2006-08-21       Impact factor: 5.742

4.  Detection of human telomerase reverse transcriptase mRNA in cells obtained by lavage of the pleura is not associated with worse outcome in patients with stage I/II non-small cell lung cancer: results from Cancer and Leukemia Group B 159902.

Authors:  Alice M Boylan; Xiaofei F Wang; Richard Ko; Patricia M Watson; Lin Gu; David Harpole; Raphael Bueno; Rosemary Kelly; Leslie Kohman; Robert Kratzke
Journal:  J Thorac Cardiovasc Surg       Date:  2012-09-29       Impact factor: 5.209

5.  Pretreatment levels of serum osteoprotegerin and p53 protein and urine telomerase as prognostic factors affecting survival in Egyptian bladder cancer patients.

Authors:  Rania Bakry; Mohamed I El-Sayed; Hesham M Hamza; Khaled H Hassan
Journal:  Oncol Lett       Date:  2015-11-17       Impact factor: 2.967

6.  Curcumin counteracts the proliferative effect of estradiol and induces apoptosis in cervical cancer cells.

Authors:  Mayank Singh; Neeta Singh
Journal:  Mol Cell Biochem       Date:  2010-10-13       Impact factor: 3.396

7.  Human telomerase reverse transcriptase protein expression is associated with survival in patients with oral squamous cell carcinoma.

Authors:  Kazuya Haraguchi; Manabu Habu; Naomi Yada; Masaaki Sasaguri; Izumi Yoshioka; Kazuhiro Tominaga
Journal:  Int J Clin Exp Pathol       Date:  2022-01-15

8.  Telomere maintenance in childhood primitive neuroectodermal brain tumors.

Authors:  Domenico Didiano; Tarek Shalaby; Doris Lang; Michael A Grotzer
Journal:  Neuro Oncol       Date:  2004-01       Impact factor: 12.300

9.  Molecular mechanism of curcumin induced cytotoxicity in human cervical carcinoma cells.

Authors:  Mayank Singh; Neeta Singh
Journal:  Mol Cell Biochem       Date:  2009-02-04       Impact factor: 3.396

10.  Anti-carcinogenic effects of the phenolic-rich extract from abnormal Savda Munziq in association with its cytotoxicity, apoptosis-inducing properties and telomerase activity in human cervical cancer cells (SiHa).

Authors:  Guzalnur Abliz; Fatima Mijit; Li Hua; Guzalnur Abdixkur; Tangnur Ablimit; Nurmuhammat Amat; Halmurat Upur
Journal:  BMC Complement Altern Med       Date:  2015-02-12       Impact factor: 3.659

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.